Delaware |
001-11460 |
31-1103425 |
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
10355 Science Center Drive, Suite 150
| ||
San Diego, CA |
92121 | |
(Address of Principal Executive Offices)
|
(Zip Code)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
| ||
Common Stock, par value $0.005 per share |
ERNA |
The Nasdaq Stock Market LLC |
Item 1.01 |
Entry into a Material Definitive Agreement.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit
Number
|
Description
| |
Form of Warrant.
| ||
Registration Rights Agreement, dated as of December 2, 2022, by and among Eterna Therapeutics Inc. and the purchasers party thereto.
| ||
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
Eterna Therapeutics Inc.
| ||
Dated: December 5, 2022
|
By:
|
/s/ Andrew Jackson |
Andrew Jackson
| ||
Chief Financial Officer
|
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Eterne Therapeutics Inc. published this content on 05 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 December 2022 11:11:23 UTC.